Giant-Cell Arteritis Market Report 2026

The giant-cell arteritis market size has grown steadily in recent years. It will grow from $1.12 billion in 2025 to $1.18 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to aging population growth, reliance on corticosteroid therapy, improved rheumatology care, expansion of hospital-based treatment, increased disease awareness.

The giant-cell arteritis market size is expected to see steady growth in the next few years. It will grow to $1.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to biologic drug approvals, growth in immunology research, improved diagnostic protocols, personalized vasculitis treatment, expansion of specialty clinics. Major trends in the forecast period include increased adoption of biologic therapies, rising focus on early and accurate diagnosis, expanded use of corticosteroid-sparing treatments, improved long-term disease monitoring, growing awareness of vision loss prevention.

Growing focus on personalized medicine is expected to drive the growth of the giant-cell arteritis market in the coming years. Personalized medicine involves customizing medical treatments to individual patient characteristics, including genetics, lifestyle, and environmental factors. Its adoption is increasing due to advancements in genomics, biotechnology, and data analytics, which allow for targeted therapies that enhance treatment effectiveness and reduce adverse effects. In the context of giant-cell arteritis (GCA), personalized medicine enables therapies tailored to patient-specific factors such as genetic predispositions, immune profiles, and disease manifestations. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, reported that personalized medicines accounted for over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. That year, the FDA approved 16 new personalized treatments for rare diseases, up from six approvals in 2022, including seven cancer therapies and three treatments for other conditions. Therefore, the growing focus on personalized medicine is driving the giant-cell arteritis market.

Major companies operating in the giant-cell arteritis market are developing new products, such as biosimilars, to expand treatment options and address unmet medical needs. A biosimilar is a biologic therapy that is highly similar to an already approved biological product, with no clinically meaningful differences in safety, purity, or potency. For instance, in April 2024, Fresenius SE & Co. KGaA, a Germany-based healthcare company, launched Tocilizumab-aazg in the U.S. for treating chronic autoimmune conditions. This biosimilar is approved for rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant-cell arteritis. Its approval was supported by data from a randomized, double-blind, single-dose, parallel phase 1 trial comparing pharmacokinetics, safety, and immunogenicity to both U.S. and EU reference tocilizumab in three patient groups.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired Teva’s manufacturing facility in Goa, India, for an undisclosed amount. The acquisition includes a 47,597-square-meter facility, enabling Marksans to double its existing production capacity in India from 8 billion units per year. This expansion allows for the production of tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceutical is an Israel-based company that manufactures prednisone tablets for the treatment of giant-cell arteritis.

Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol‑Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB.

North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the giant-cell arteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the giant-cell arteritis market by increasing costs of imported biologic drugs, diagnostic imaging equipment, and laboratory reagents. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported therapies. These tariffs raise treatment costs by increasing expenses for biologic therapy and advanced diagnostic imaging, impacting long-term disease management. However, they support domestic biologics manufacturing, strengthening regional capabilities for immunologic therapies.

The giant-cell arteritis market research report is one of a series of new reports that provides giant-cell arteritis market statistics, including giant-cell arteritis industry global market size, regional shares, competitors with a giant-cell arteritis market share, detailed giant-cell arteritis market segments, market trends and opportunities, and any further data you may need to thrive in the giant-cell arteritis industry. This giant-cell arteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Giant-cell arteritis (GCA) is a type of vasculitis, or inflammation of blood vessels, primarily affecting medium to large arteries. It often involves the temporal arteries, causing symptoms such as headaches, scalp tenderness, and vision problems. GCA is marked by inflammation of the vessel walls, which can lead to serious complications like blindness or stroke if left untreated. Treatment usually involves high-dose corticosteroids to reduce inflammation and prevent complications.

The main therapeutics for giant-cell arteritis include prednisone, methotrexate, tocilizumab, and aspirin. Prednisone is a corticosteroid that reduces inflammation and suppresses the immune system. Its mechanisms of action include corticosteroid activity, immunosuppression, anticoagulation, and others. Prednisone can be administered orally, intravenously, subcutaneously, and through other routes.

The giant-cell arteritis market consists of revenues earned by entities by services such as monitoring and follow-up, supportive care, diagnostic testing, treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The giant-cell arteritis market also includes sales of biologics, diagnostic tools, biopsy kits and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.